Yubo International Biotech Reports Q3 2025 Financial Results with Reduced Net Loss

Yubo International Biotech Limited reported its financial results for the third quarter of 2025, revealing a net loss of $310,152, a decrease from a loss of $621,053 in the same period of 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $902,288, compared to a loss of $1,628,906 for the same period in the previous year. The company did not generate any revenue from product sales during the third quarter or the first nine months of 2025, contrasting with $3,488 in revenue for the nine months ended September 30, 2024. Operating expenses for the third quarter were $310,134, down from $532,764 in the prior year, indicating a significant reduction in costs.

The company’s total assets decreased to $953,211 as of September 30, 2025, from $1,534,832 at the end of 2024. This decline was primarily driven by a reduction in current liabilities, which fell to $2,555,316 from $4,721,749, largely due to a decrease in amounts due to related parties. The company’s cash position improved slightly, with cash and cash equivalents rising to $10,926 from $7,015 at the end of 2024. The total deficit attributable to common shareholders was reported at $(1,662,888), a notable improvement from $(3,424,464) at the end of the previous fiscal year.

Strategically, Yubo International Biotech has made significant organizational changes, including the issuance of 50,600,343 shares of Class A common stock in July 2025, which was part of a transaction to settle shareholder loans. This move increased the total shares outstanding to 170,416,343 as of September 30, 2025. The company has also been active in expanding its operations, acquiring Phoenix Club Bio-Medical Technology (Chengdu) Co., Ltd. in October 2023, and increasing its stake in EpiAis Biomedical Engineering (Shenzhen) Co., Ltd. to 70% in September 2024.

Operationally, Yubo International Biotech has not reported any significant customer counts or product adoption rates, as it has not generated revenue from product sales in the current fiscal year. The company continues to face challenges in establishing a sustainable revenue stream, which raises concerns about its ability to continue as a going concern. Management has indicated that additional capital resources will be necessary to meet operating expenses and has plans to seek funding from management and significant shareholders. The company’s outlook remains cautious, with ongoing risks related to its variable interest entity structure and regulatory environment in China, which could impact its operations and financial performance.